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A multidisciplinary expert review of key issues and future directions from the conference 
“Controversial labels and clinical uncertainties: psychogenic disorders, conversion disor-
der, and functional symptoms.”
On October 9 and 10, 2015, a conference entitled “Controversial labels and clinical 
uncertainties: psychogenic disorders, conversion disorder, and functional symptoms” 
was held at the Center for Ethics, Emory University, Atlanta, GA, USA. This conference 
brought together a select group of 30 distinguished thought leaders and practitioners, 
including ethicists, researchers, clinicians, humanities scholars, and advocates to discuss 
the unique challenges and controversies related to the diagnosis, treatment, and stigma 
for patients with what is currently recognized as functional (“psychogenic”) neurological 
disorders. Our group of experts explored the conflicts and ethical tensions within health 
care that must be addressed in order to advance care for these disorders. What follows is 
a reflection on the conversations between conference attendees outlining key challenges 
and value conflicts in the diagnosis and treatment of patients with functional disorders. 
With this report, we aim to provide a roadmap for reducing stigma and improving care 
for functional neurological disorders (FND). A path forward would involve (1) setting a 
multifactorial research agenda that equally prioritized access to effective psychotherapy 
as well as identification of novel biomarkers; (2) empowering patients with FND to be 
heard and to drive changes in care; and (3) reducing isolation for clinicians by providing 
formal training and setting up multidisciplinary care teams and support networks.
Keywords: psychogenic, conversion, functional neurological disorders, medically unexplained illness, stigma, 
education, neuroethics, multidisciplinary care
iNtrODUctiON
Functional neurological disorders (FND) are conceptualized as a manifestation of neurological 
symptoms that arise from a psychiatric origin. FND represents a confounding situation where an 
otherwise invisible illness becomes visible. As Jakes story illustrates (Box 1), FND lacks owner-
ship; an orphan to a disciplinary home in medicine, falling in the netherworld of thew neurology-
psychiatry abyss. The high prevalence, poor prognosis, lack of available treatments, and the fact that 
patients often have disbelief in their diagnosis has lead to a “A crisis for neurology” (1). However, 
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any clinician who find themselves in the position of caring for 
such patients are faced with a dearth of resources including a 
lack of formal training, guidelines, standards of care, referral 
options, and emotional support. Because of this need to address, 
the overwhelming challenges of FND, on October 9 and 10, 2015, 
“Controversial labels and clinical uncertainties: psychogenic disor-
ders, conversion disorder, and functional symptoms” was held at 
the Center for Ethics, Emory University, Atlanta, GA, USA. This 
conference brought together a selected group of 30 distinguished 
thought leaders in the field including ethicists, researchers, clini-
cians, humanities scholars, and advocates to discuss the unique 
challenges and controversies related to the diagnosis, treatment, 
and stigma for patients with functional (“psychogenic”) disor-
ders. Conference attendees aimed to outline key challenges in the 
diagnosis and treatment of patients with functional disorders. We 
asked: What value conflicts exist across healthcare professionals and 
patients that create hurdles for care? How can biased attitudes affect 
diagnosis and treatment? What are the research priorities needed 
for developing a standard of care? What controversies require 
further exploration in a larger forum? Within the framework of 
these four questions, we utilized category prompts (Box S1 in 
Supplementary Material) to focus our discussions on diagnosis, 
treatment, physician training, and infrastructure challenges. 
In this report, we, the conference organizers, aim to describe, 
summarize, synthesize many varied voices that were represented 
at the conference. What follows is a reflection, from the authors, 
on these conversations and a roadmap guided by the conversa-
tions with conference attendees, for reducing stigma and advanc-
ing care for FND.
About FND
There is no known biological etiology for FND, and the lack of 
mechanistic understanding is reflected in the terminologies used 
by neurologists and psychiatrists and lack of clear disciplinary 
home for FND. The term “psychogenic,” most preferred by 
neurologists according to a 2009 survey (2), describes disorders 
manifesting with physical conditions that cannot be attributed 
to underlying organic pathology (3, 4). A direct etymylogical 
interpretation suggests a genesis within the psyche or soul reveal-
ing the admonishing undertones to those who have come to be 
afflicted with a sick soul. While some neurologists have advocated 
for a change from “psychogenic” to “functional” (5), there are 
others who argue that “functional” introduces more ambiguity 
with historical roots intertwined with terms like “hysteria” (6). 
Psychiatrists may refer to these disorders as conversion disorder, 
but in our conference, psychiatrists were quick to remind us that 
a “psychogenic” diagnosis is not synonymous with conversion 
because they do not necessarily meet Diagnostic and Statistical 
Manual of Mental Disorders (DSM) criteria. For the purpose of 
this paper, we choose to use the term “functional” in deference 
to the language of choice of patient advocacy organizations 
Functional Neurological Disorders Hope (FNDHope) and 
ProjectFND.
Functional movement disorders (FMDs) are among the more 
common FND (3), affecting up to 25% of patients who visit spe-
cialized movement disorder clinics (7). Epidemiological studies 
suggest that some FMDs, such as functional tremor, have a higher 
incidence than “organic” neurological disorders such as multiple 
sclerosis or amyotrophic lateral sclerosis [for review, see Nowak 
and Fink (3)] and experience worse quality of life and severity 
of disability scores compared to “organic” movement disorders 
including Parkinson’s disease (8). Long-term follow-up studies 
reveal a poor prognosis with 50–90% of FMD patients experienc-
ing ongoing symptoms (9–11), many of whom become worse, 
especially when treatment begins later than 6–12 months from 
symptom onset (12, 13). Non-epileptic seizures, are not associ-
ated with epileptic discharges, yet manifest paroxysmal, invol-
untary alterations in motor, sensory and/or behavioral function 
that resemble epileptic seizures (14). Functional (psychogenic) 
non-epileptic seizures (PNES), like FMDs, are presumed to be 
caused by psychological distress and have been reported to affect 
up to 30% of patients who are referred to epilepsy centers (15, 
16). Quality of life scores are often worse than patients with 
refractory epilepsy (17). Patients with FND often experience 
multiple referrals, frequent office visits, as well as expensive, 
sophisticated, and invasive tests (8). It is important to note that 
FND have many other motor and sensory manifestations such 
as weakness (18) and paralysis (3) to name a few. The estimated 
annual US healthcare costs from FMD alone is at least $20 billion 
(19, 20).
False Distinctions: the Not-so-Bright Line 
between Neurology and Psychiatry
The crisis of FND is a crisis of ideology, a direct product of a 
spuriously perceived division between neurology and psychiatry. 
Neurologists take care of the body and psychiatrists tend to the 
mind. Such a separation has had a negative impact on treatment, 
by creating tangible health-care infrastructure challenges and 
gaps in care, and neglect from funding agencies, making FND 
orphan to a medical treatment home. The disciplinary divide 
holds explanatory power to patients and clinicians alike. A dif-
ferent kind of moral judgment is cast depending upon whether 
one conceptualizes FND as etiologically a neurological or mental 
disorder. If the patient has a diseased mind, the patient is more 
blameworthy for the illness; if the patient has a diseased body, 
then the patient is less responsible (21). In fact, the DSM (22) 
BOX 1 | Patient Narrative.
Jake suddenly developed a constellation of symptoms including stumbling 
gait, jerking movements, and impaired speech. Alarmed and concerned, his 
family rushed him to the emergency department (ED). The ED physician told 
him awkwardly that they could find no abnormalities on his evaluation, that they 
could not explain his illness, and recommended a neurologist. The neurologist 
indicated to him that his symptoms were likely psychological and that in fact, 
this was good news because it was not serious. He was then instructed to see 
a psychiatrist. Jake reluctantly went to the psychiatrist who said, “You don’t 
need to see me; you have no clear psychiatric illness yet very clear physical 
manifestations.” Jake left feeling embarrassed and angry, believing “the docs 
think this is all in my head and that I’m making this up.” Jake continued to see 
many providers looking for an answer. They appeared to dread seeing him and 
wondered if he was malingering or feigning illness. Jake and his family were 
left feeling frustrated and helpless. His symptoms remained unresolved, and 
he has now amassed tremendous health-care expenditures.
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distinguishes functional disorders (conversion disorder) from 
intentional maladies such as malingering or factitious disorder, 
however, neurologists do not universally accept this distinc-
tion with the conviction that a patients’ conscious intention to 
manifest in functional symptoms is not possible to determine or 
differentiate (4, 12). A rich discussion on policing this divide con-
tinues to brew significant discontent in the medical community 
today (23–25). There is so much allegiance to this division that 
any attempt to blur the line between neurology and psychiatry 
is cause for unrest, a veritable affront to the natural moral and 
social order.
stigma and FND
In the case scenario (Box S1 in Supplementary Material), we 
see that Jake is left feeling confused and frustrated. Despite the 
neurologist’s view that the diagnosis is “good news,” he is told 
he should see a mental health-care provider. Why the mismatch? 
For those with FND, there is a stigma ascribed to having mental 
illness as the cause of their symptoms. Stigma is a cognitive fram-
ing or worldview that leads to stereotyping, prejudice, and unjust 
discriminatory acts (26). With stigma, negative evaluations lead 
to negative emotions. Ultimately, these negative evaluations lead 
to punitive measures such as removing rightful opportunities (in 
the case of FND, appropriate health care), avoidance of stigma-
tized parties, and overall deleterious treatment of those who are 
the subject of the stigma (26, 27).
Stigma, represented by three forms: public stigma, self-stigma, 
and avoidance for the label itself (26), is eminently present in 
those with FND. Public stigma is represented by the avoidance 
and withdrawal of many clinicians from patients with FND. 
Patients with FND are seen as a risk, requiring an inordinate 
amount of time (at least more than physicians may be typically 
allotted for routine patients) and introduce personal discomfort 
in physicians who feel they have lack of expertise and resources 
to properly care for these patients. There is also fear of litiga-
tion. Self-stigma, wherein the subject of the stigma internalizes 
the prejudice and discrimination, is also a significant hurdle 
for FND. It is clear that the reluctance to accept a diagnosis of 
“psychogenic,” “conversion,” or any derivative thereof, as well 
as avoidance of mental health care, is active efforts to distance 
oneself from a label that patients fear is socially unacceptable. 
There is no label for FND that will eliminate stigma. Eliminating 
stigma requires more than revising our terminology. Stigma is 
about the pernicious associated meaning of undesirable differ-
ence and otherness that leads to prejudice, discrimination, and 
social exclusion. The label is only a signifier, and the meaning will 
follow regardless of a new name.
can a Biological explanation eliminate 
stigma from FND?
Suggesting that mental illness is a biological disorder has, accord-
ing to some, at least partially mitigated stigma (21). Rebranding 
psychiatry by conceptualizing “disorders of the mind as disorders 
of the brain” has been advocated (28). The hope with such a strat-
egy is that an authoritative representation of a biological disorder 
will somehow legitimize (or perhaps materialize) the patient’s 
symptoms and suffering (29). However, a number of studies 
have suggested that even with increased knowledge about mental 
illnesses and their status as “brain disorders,” stigma has been 
relatively unchanged over the past two decades (30). Attributing 
mental illness to a biological origin brings its own brand of stigma 
(i.e., assumptions that people who are mentally ill are biological 
weaker, cannot recover, and are perhaps even dangerous) (26).
Choudhury et al. (31) warned against the oversimplification 
of the mental as merely biological phenomena, “the reduction of 
psychiatry to neurobiology tends to neglect the phenomenological 
insights, biographical accounts of the person and the meaning—
that is, the social, cultural, moral, or spiritual significances—of 
mental illness or interventions” (31). FND requires a more holistic 
psychosocial–biological model rather than reducing people to, as 
Dumit says, merely “objects of science and medicine” (32). This is 
not to say that as more biological correlates of FND are discovered 
they should be ignored. Recent neuroimaging data suggests that 
FMD patients suffer from sensory deficits and impaired perceived 
“voluntariness” (3, 33), while patients with PNES have evidence 
of altered functional and structural connectivity (34). While 
this work is in its infancy, these findings can help patients and 
clinicians have fruitful conversations that disrupt assumptions 
about the nature of FND. As comforting as employing biological 
explanations for these disorders may be, these correlates are not 
the panacea to stigma. Such a strategy can implicitly endorse 
a classification system that would, in turn, oversimplify these 
disorders and foreclose a more holistic view while preventing a 
multidisciplinary treatment approach.
APPrOAcHes tO DisrUPt 
BOUNDAries, reDUce stiGMA, 
AND ADvANce cAre
encourage Multidisciplinary research
To transform care, FND must be appreciated in its full complex-
ity: psychosocial–biological. Working toward a multidisciplinary 
research agenda is a critical step toward advancing diagnosis, treat-
ment, and long-term care for patients with FND. Interventions, 
thus far, have been wide-ranging including psychodynamic 
therapy, hypnosis, cognitive behavioral therapy, biofeedback, 
physical therapy, transcranial magnetic stimulation, and medica-
tions including antidepressants (3, 35); however, there is a strik-
ing paucity of randomized controlled trials (36–40). Resources 
should be aimed at making psychological therapy options more 
accessible while providing opportunities to gain biological 
insights. Identifying biomarkers utilizing clinical neurophysiol-
ogy (EEG/EMG) and neuroimaging [fMRI and DATscans (41)] 
must be given equal priority to research on psychotherapeutic 
treatment options (i.e., cognitive behavioral therapy, dialectical 
behavior therapy, and supportive therapy).
It is clear that we are far from identifying the most effective 
treatment approach given the heterogeneity of the FND. But it is 
agreed upon that treatment must be individualized. Goals must 
also be constructed with patients and their families to provide 
insight into the treatment plan and feedback of successful com-
munication strategies between clinicians and patients must be 
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maintained throughout the process (42). These goals may vary 
from patient to patient and across various stages of each person’s 
treatment. Initial treatment goals might include reduction in 
acute care utilization (ED visits) and prevention of iatrogenic 
harm from unnecessary interventions. Goals can then progress to 
bringing patients into remission. In such a scenario, quality of life 
improvements and cost savings can be achieved even if patients 
are not cured, but instead helped to cope or “live with” FND.
Prospective studies that evaluate natural history will assist 
clinicians in making more accurate and confident diagnoses; for 
example, exploring the percentage of patients that spontaneously 
remit, develop new symptoms, or whether symptoms return after 
remission. Another valuable area to explore would be predictors 
of FND (biological, social, and cultural factors) by comparing 
patients with unaffected family members or predictors of recov-
ery. Finally, new tools should be developed to assess outcomes 
for determination of successful treatment. Tools might include 
accelerometry, motion-capture devices, and improved measures 
for quality of life, pain, anxiety, and mood. As discussed below, 
research evaluating new multidisciplinary models of care and 
standardized joint-training curriculum should also be conducted 
in order to generate adaptable care and training models.
create Opportunities for Patient 
empowerment
The professional’s expertise in managing health-care services 
does not necessarily translate to insight into the social sphere 
surrounding the patient’s experience. Patients, families, and 
advocates must also help drive research priorities. FNDHope, 
the first non-profit advocacy organization for patients with FND 
originating in the UK, has already begun to create a database 
of patients interested in participating in future studies. Such a 
database not only addresses challenges in small recruitment pools 
for FND studies but also engages patients as participants as well 
as advisors in creating a future research agenda.
Part of clinician education must require all stakeholders, espe-
cially those patients who live with FND and can share insights 
into their lived experience. Patient and physician perspectives, 
collected through qualitative interviews and surveys, can inform 
new research directions, highlight conceptual struggles, and 
on-the-ground areas for improvement in clinician training, diag-
nosis, and treatment (42–47). Education programs that involve 
direct contact with patients, outside of the clinic, have been 
shown to reduce stigma perceptions of “otherness” promoting 
deeper understanding and appreciation for these disorders (48). 
Such an approach makes the patients part of the conversation, 
which is empowering. Parity (not pity) and empowerment of 
individuals who are of the stigmatized group, in this case those 
with FND, who already feel captive to their bodies, can feel hope 
and enabled to pursue their life goals in a self-determined way. 
We have begun implementing this approach to highlight personal 
narratives at our inaugural conference, where we included the 
president of FNDHope and also plan to continue and expand 
upon this tradition by inviting paired clinician–patient narratives 
in our 2017 conference as well as including patient, family, and 
advocate representatives.
reduce Professional isolation through 
training
Care providers, not unlike their patients with FND, often feel they 
are in a microcosm of ambiguity and frustration. Clinicians often 
have few resources having likely received little formal training 
and even less time to care for these patients and no sense of 
solidarity and community. So how might we do better to support 
our clinicians?
While there are some efforts toward clinician community 
building and training for FND (for example, the Functional 
Neurological Forum http://fnforum.org), our group felt a 
conspicuous lack of formalized curriculum in FND in medical 
school, residency, and beyond. A robust multifactorial approach 
to FND education can offer providers, patients, and advocates 
an arsenal of evidence and facts to dispel myths and stereotypes 
that undermine care for these patients. This would include not 
only the latest neurophysiological research and exploration of 
psychotherapeutic approaches but also social science data such as 
narratives about patient and family experiences and how stigma 
impacts clinician practices.
Acknowledging to patients that FND is a significant medical 
condition requiring intervention for improvement of symptoms 
is of utmost importance. Word choice (including what is said 
and left unsaid) can have enormous impact on the therapeutic 
encounter both for better and worse (43). Confronting patients 
with FND can be accompanied by powerful feelings of vulner-
ability, helplessness, and frustration. Incorrect physician (and 
perhaps even patients’) assumptions and biases (i.e., “FND 
only impacts young women.”) can impact rate of diagnosis and 
treatment programs (49). There is shame associated with FND 
both from patients who have internalized the stigma of their 
diagnosis and from the clinicians (50) who are not quite sure 
how to care for them once the diagnosis is given (a diagnosis 
for which they may have their own doubts). The path forward 
is not simple. Stigma and tolerance of ambiguity must be 
discussed openly in training and amongst treating clinicians 
and patients. Clinicians must challenge their own underlying 
views on functional disorders. They must ask how uncertainty 
and discomfort with FND patients, or how privileging of the 
biological over mental disorders, might contribute to their felt 
or enacted stigma toward FND.
Because the disclosure of diagnosis can be complex, the use of 
a standardized non-judgmental script, such as outlined by Stone 
(51) as well as external review of the delivery of that script should 
be a critical part of ongoing training efforts. A video repository 
demonstrating strategies of delivering the diagnosis and com-
munication with the patient could be integrated into training. 
Training modules for medical students and residents—similar to 
those created by the Accreditation Council for Graduate Medical 
Education (ACGME) (52)—could be adapted for discussing the 
complex nature of FND diagnosis and treatment as well as how 
to respond to challenging questions (“so you are saying this is all 
in my head,” “you don’t believe me?”).
Joint and cross-disciplinary training about FND for all mem-
bers in the health-care team should be emphasized and started 
as early as medical school. Recent cross-disciplinary training 
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efforts within the ACGME Psychiatry and Neurology Milestone 
Projects (53, 54) are a positive direction for FND training. 
Medical student/resident training is debated as being quite full 
(55); however, strategies as simple as providing greater emphasis 
on existing training such as bedside teaching and modeling 
would be helpful. Additional modules could also be built into 
continuing education programs for any health-care provider who 
might encounter patients with FND including psychologists, 
social workers, physical therapists, nurses, general practitioners 
and ED physicians, surgeons, and any physician who might 
encounter a patient with FND.
establish collaborative Multidisciplinary 
care teams
We propose that a multidisciplinary care team would provide the 
best opportunity for advanced treatment for patients with FND. 
While not without its challenges, patients with FND would most 
benefit from such coordinated care where a consistent message 
is conveyed avoiding the often present ambiguities currently 
seen that confuse the patients. In alignment with the most recent 
DSM-V revision on conversion disorder (56), many conference 
participants believed that neurology was an important point of 
entry for patients particularly for their expertise in diagnosing 
these disorders. However, after this initial referral, the coordina-
tion between specialists must be seamless and communication 
open. Some existing efforts of collaborative teams include a 2012 
report from the National Health Service in Scotland that calls 
for a “integrated neuropsychiatry and clinical neuropsychol-
ogy service” that includes a team of neurologists, neuroscience 
nurses, liaison psychiatrists and neuropsychiatrists, clinical 
neuropsychiatrist, rehabilitation service, and such an collabora-
tive approach continues to be recommend (57, 58). Members 
of our organizing committee are piloting a multidisciplinary 
specialty clinic wherein patients, who have received an initial 
referral from a neurologist, are able to receive a complete 
evaluation and delivery of diagnosis by a care team including 
a neurologist, psychiatrist, psychologist, physical therapist, 
and social worker. The multidisciplinary team creates a treat-
ment plan tailored to fit the unique history and manifestation 
of the patient’s symptoms. For example, the behavioral health 
component might include a biopsychosocial assessment as well 
as recommendations for concomitant mood symptoms by a 
psychiatrist. Follow-up referrals for mental health treatment 
could be made in coordination with referrals to other special-
ties including physical therapy, occupational therapy, and other 
related fields. Some of the authors have found that follow-up, 
even as simple as routine phone calls, can help patients become 
more responsive to recommendations and have significantly 
better outcomes (59). Just as the neurologist is a critical point 
of entry into care, the neurologist is also critical for monitor-
ing care. Ultimately, the neurologist must “take ownership” of 
the patient’s care. The neurologist must be afforded the time to 
maintain patient contact and monitor the care process in follow-
up visits. Incorporating telemedicine for long-term follow-up 
might be beneficial for patients who do not live in close proxim-
ity to specialists on the care team. Annual evaluations in the 
interdisciplinary clinic might also be considered if needed. The 
group also proposed a set of simple instructions, such as a flow 
chart, as a resource for ED doctors, and other first line provid-
ers that can avoid fragmented care and harm to these patients. 
Physicians who frequently care for patients with FND also need 
their own support by working in a team and perhaps the forma-
tion of support groups. Having a trusted team can help decrease 
care and reduce provider burnout.
A clear hurdle in improving care for patients with FND is 
the gap in detailed health economics analysis. What are the cost 
burdens? Who is bearing such costs? While health-care systems 
should be in the business of promoting wellness, they are equally 
concerned with cost avoidance. Basic health-care economics 
research needs to be conducted to help compel structural changes 
in the current health-care system, which is failing patients with 
FND. One critical area for future research would include pre- and 
post-intervention assessments, particularly in the context of a 
multidisciplinary treatment model. Such assessments could aid 
in determination of the cost of caring of an individual patient 
with FND in the 12 months before and after intervention. Similar 
research in palliative care was able to demonstrate dramatic sav-
ings for US hospitals with investments in palliative care (60), and 
we believe the same can be achieved with a multidisciplinary 
model for FND. A critical component to this analysis would 
include assessment of clinician, patient, and family perspectives 
in order to recognize successes as well as areas for improvement. 
This data can also facilitate the creation of an exportable model 
of care for patients with FND.
cONcLUDiNG reMArKs
We believe it is time to transform the status of FND from a crisis 
to a priority. A path forward would involve (1) setting a multifac-
torial research agenda that equally prioritized access to effective 
psychotherapy as well as identification of novel biomarkers; (2) 
empowering patients with FND to be heard and to drive changes 
in care; and (3) reducing isolation for clinicians by providing 
formal training and setting up multidisciplinary care teams, and 
support networks. Coordination of care and cross-disciplinary 
training would greatly facilitate patient wellness by addressing 
the multifactorial nature of FND and avoid redundancy in gaps 
of care. All of these advances must be accompanied by frank and 
honest discussions about stigma rather than a circular conversa-
tion about whether FND is a neurological or psychiatric disorder 
or what name it should bear while solutions are co-created with 
patients, families, and advocates.
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